| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/22/2007 | CA2212200C Novel inhibitors of .beta.-glucuronidase |
| 05/22/2007 | CA2208241C Stable solutions of 2-chloro-2'-deoxyadenosine formulations |
| 05/22/2007 | CA2206296C Low rigidity liposomal antibacterial composition |
| 05/22/2007 | CA2192093C Agonists and antagonists of the nicotinic acetylcholine receptors of insects to control endoparasites |
| 05/22/2007 | CA2186133C Retinal-containing composition |
| 05/22/2007 | CA2174327C Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women |
| 05/22/2007 | CA2171460C Preparation for substitution therapy, containing at least one progestogen and at least one extrogen |
| 05/22/2007 | CA2162232C Cerebration improver |
| 05/22/2007 | CA2157579C Heterocyclic compounds, their use and preparation |
| 05/22/2007 | CA2157146C Heterocyclyl-benzoylguanidines |
| 05/22/2007 | CA2156922C Fluorocarbon emulsions with reduced pulmonary gas-trapping properties |
| 05/22/2007 | CA2069084C 1.alpha.-hydroxy vitamin d4 and novel intermediates and analogues |
| 05/18/2007 | WO2007056771A2 Compounds for the treatment of metabolic disorders |
| 05/18/2007 | WO2007056701A2 Nutrient extracts derived from green plant materials |
| 05/18/2007 | WO2007056683A2 Novel chemical compounds |
| 05/18/2007 | WO2007056625A2 Thienopyridine b-raf kinase inhibitors |
| 05/18/2007 | WO2007056618A1 Compositions and methods for the treatment of addiction and other neuropsychiatric disorders |
| 05/18/2007 | WO2007056593A2 α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
| 05/18/2007 | WO2007056582A1 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| 05/18/2007 | WO2007056580A2 Methods and compositions for treating diseases associated with pathogenic proteins |
| 05/18/2007 | WO2007056556A2 Polyethylene glycol conjugates of pyridinium and thiazolium compounds and methods of using the same |
| 05/18/2007 | WO2007056546A1 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
| 05/18/2007 | WO2007056525A2 High affinity siglec ligands |
| 05/18/2007 | WO2007056513A1 α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS |
| 05/18/2007 | WO2007056500A2 Compounds with activity at estrogen receptors |
| 05/18/2007 | WO2007056497A1 Compounds and compositions as ppar modulators |
| 05/18/2007 | WO2007056496A1 Oxazole and thiazole ppar modulator |
| 05/18/2007 | WO2007056491A2 Film-forming resins as a carrier for topical application of pharmacologically active agents |
| 05/18/2007 | WO2007056469A2 Certain chemical entities, compositions, and methods |
| 05/18/2007 | WO2007056468A1 Methods for inhibiting protein kinases |
| 05/18/2007 | WO2007056457A2 Methods, compositions, and kits for the treatment of medical conditions |
| 05/18/2007 | WO2007056454A2 Use of cicletanine and other furopyridines for treatment of hypertension |
| 05/18/2007 | WO2007056439A1 Salts of methylene blue and its derivatives |
| 05/18/2007 | WO2007056424A2 Controlled-release emulsion compositions |
| 05/18/2007 | WO2007056389A2 Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases |
| 05/18/2007 | WO2007056387A2 Combinations of metformin and meglitinide |
| 05/18/2007 | WO2007056376A2 Compositions for regulating metabolic disorders and methods of use thereof |
| 05/18/2007 | WO2007056366A2 Compounds and compositions as ppar modulators |
| 05/18/2007 | WO2007056341A1 Heterocyclic modulators of atp-binding cassette transporters |
| 05/18/2007 | WO2007056340A2 Disinfectant and antiseptic pyridinium and thiazolium compounds and methods of using the same |
| 05/18/2007 | WO2007056335A2 Methods of sensitizing cancer to therapy-induced cytotoxicity |
| 05/18/2007 | WO2007056330A1 Benzimidazole derivatives as gyrase inhibitors |
| 05/18/2007 | WO2007056324A2 Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| 05/18/2007 | WO2007056316A2 Injectable physiological temperature setting cement composites for spinal fusion and related method thereof |
| 05/18/2007 | WO2007056300A2 Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| 05/18/2007 | WO2007056280A1 Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors |
| 05/18/2007 | WO2007056279A2 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| 05/18/2007 | WO2007056275A2 Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors |
| 05/18/2007 | WO2007056264A2 Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| 05/18/2007 | WO2007056263A2 Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| 05/18/2007 | WO2007056244A2 Methods of using saha and erlotinib for treating cancer |
| 05/18/2007 | WO2007056243A2 Methods of treating cancers with saha and fluorouracil and other combination therapies |
| 05/18/2007 | WO2007056236A2 Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
| 05/18/2007 | WO2007056232A2 Methods of using saha and bortezomib for treating cancer |
| 05/18/2007 | WO2007056228A2 5-lipoxygenase-activating protein (flap) inhibitors |
| 05/18/2007 | WO2007056221A2 Aminopyrimidines useful as kinase inhibitors |
| 05/18/2007 | WO2007056220A2 5-lipoxygenase-activating protein (flap) inhibitors |
| 05/18/2007 | WO2007056219A2 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| 05/18/2007 | WO2007056217A2 Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound |
| 05/18/2007 | WO2007056215A2 N-aryl-thienopyrimidin-4-amines and the use thereof |
| 05/18/2007 | WO2007056214A2 N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
| 05/18/2007 | WO2007056213A2 Drug-eluting stents coated with p2y12 receptor antagonist compound |
| 05/18/2007 | WO2007056210A2 Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis |
| 05/18/2007 | WO2007056208A2 N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 05/18/2007 | WO2007056188A1 Synthesis of inhibitors of ftsz |
| 05/18/2007 | WO2007056184A2 Azaindole compounds and use thereof as phospholipase-a2 inhibitors |
| 05/18/2007 | WO2007056170A2 Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| 05/18/2007 | WO2007056167A2 Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof |
| 05/18/2007 | WO2007056164A2 Aminopyrimidines useful as kinase inhibitors |
| 05/18/2007 | WO2007056163A2 Aminopyrimidines useful as kinase inhibitors |
| 05/18/2007 | WO2007056162A2 Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
| 05/18/2007 | WO2007056159A2 Hydrazone derivatives and uses thereof |
| 05/18/2007 | WO2007056155A1 Heterocyclic compounds as tyrosine kinase modulators |
| 05/18/2007 | WO2007056151A2 Protein kinase inhbitors |
| 05/18/2007 | WO2007056143A2 Certain chemical entities, compositions, and methods |
| 05/18/2007 | WO2007056142A2 Methods of preventing the serotonin syndrome and compositions for use therefor |
| 05/18/2007 | WO2007056135A1 Method of treating cancers with saha and pemetrexed |
| 05/18/2007 | WO2007056117A1 Antineoplastic combinations of temsirolimus and sunitinib malate |
| 05/18/2007 | WO2007056112A2 Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
| 05/18/2007 | WO2007056099A2 Inhibitors of ion channels |
| 05/18/2007 | WO2007056091A2 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof |
| 05/18/2007 | WO2007056087A1 Prostaglandins and analogues as agents for lowering intraocular pressure |
| 05/18/2007 | WO2007056086A2 Rifamycin analogs and uses thereof |
| 05/18/2007 | WO2007056078A2 Certain chemical entities, compositions, and methods |
| 05/18/2007 | WO2007056075A2 Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
| 05/18/2007 | WO2007056068A2 Macrocyclic formulations for transmembrane drug delivery |
| 05/18/2007 | WO2007056056A2 Mitotic kinesin inhibitors |
| 05/18/2007 | WO2007056046A1 P2x7 receptor antagonists and methods of use |
| 05/18/2007 | WO2007056023A2 Thiazole inhibitors targeting resistant kinase mutations |
| 05/18/2007 | WO2007056021A2 5-lipoxygenase-activating protein (flap) inhibitors |
| 05/18/2007 | WO2007056016A2 Bisamide cytokine inhibitors |
| 05/18/2007 | WO2007055992A2 The use of apoptotic cells ex vivo to generate regulatory t cells |
| 05/18/2007 | WO2007055982A2 Therapies for the regulation of insulin and glucose using rlip76 |
| 05/18/2007 | WO2007055942A2 Substituted nicotinamide compounds |
| 05/18/2007 | WO2007055941A2 Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
| 05/18/2007 | WO2007055928A1 5-membered ring metanicotine analogs |
| 05/18/2007 | WO2007055890A2 Co-administration of dehydroepiandrosterone (dhea) congeners and other active agents for treating cancer |
| 05/18/2007 | WO2007055885A2 Pharmaceutical gallium compositions and methods |
| 05/18/2007 | WO2007055806A1 Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids |
| 05/18/2007 | WO2007055804A2 Methods and compositions for administration of iron for the treatment of restless leg syndrome |